ReviewThe journal of headache and pain2012

The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.

Peer C Tfelt-Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.